Literature DB >> 2007927

Different forms of chronic childhood thrombocytopenic purpura defined by antiplatelet autoantibodies.

P Imbach1, P Tani, W Berchtold, V Blanchette, A Burek-Kozlowska, H Gerber, P Jacobs, A Newland, C Turner, L Wood.   

Abstract

To determine whether detection of antiplatelet autoantibodies (AAb) to glycoproteins IIb/IIIa and Ib/IX may be useful in defining different forms of chronic thrombocytopenic purpura (TP) in children, we analyzed for AAb the platelet and plasma samples from 36 children with chronic TP (mean duration 4.4 years), from 31 children with normal platelet counts at the time of blood sampling but with chronic TP in the past (mean duration 2.9 years), and from 23 adults with chronic TP; the results were correlated with the clinical data. Antiplatelet autoantibodies were detected in 26 (72.2%) of 36 children with ongoing TP, 15 (48.4%) of 31 children with TP in the past, and 12 (66.7%) of 18 adults with TP. All children with high AAb ratios (greater than 5 times the control mean + 3 SD) were more than 8 years of age at diagnosis (mean age 12.4 years compared with 7.1 years in children with moderate or negative AAb levels; p = 0.003). The results suggest that the outcome for adolescents with high platelet-associated AAb levels may be similar to that of adults, whereas younger children may have a greater chance of spontaneous remission. The children with chronic TP in the past and elevated platelet-associated AAb levels may have a "compensated" TP and therefore may be at risk for relapses. Future studies aimed at serial AAb determination throughout the patients' courses may further define TP subgroups.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007927     DOI: 10.1016/s0022-3476(05)83373-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  7 in total

1.  Laboratory investigation of immune thrombocytopenia.

Authors:  M Warner; J G Kelton
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

Review 2.  Immunthrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity.

Authors:  P Imbach; J Akatsuka; V Blanchette; A Burek-Kozlowska; J Bussel; G Gaedicke; A Gianella-Borradori; E Gugler; A Hirt; B Imholz
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

Review 3.  Harmful and beneficial antibodies in immune thrombocytopenic purpura.

Authors:  P A Imbach
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

4.  HLA class-I and -II antigens in chronic idiopathic autoimmune thrombocytopenia.

Authors:  A Gaiger; A Neumeister; H Heinzl; I Pabinger; S Panzer
Journal:  Ann Hematol       Date:  1994-06       Impact factor: 3.673

5.  Coincidence of familial platelet glycoprotein Ib/IX deficiency (Bernard-Soulier syndrome), idiopathic autoantibody against platelet glycoprotein Ib/IX, familial appearance of antiphospholipid antibodies, and familial factor XII deficiency.

Authors:  W Korte; C Baumgartner; A Feldges; C Knöpfl; S Lutz; A Lenz; W Riesen; L Schmid
Journal:  Ann Hematol       Date:  1994-02       Impact factor: 3.673

6.  Anti-platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications.

Authors:  David E Schmidt; Katja M J Heitink-Polle; Leendert Porcelijn; C Ellen van der Schoot; Gestur Vidarsson; Marrie C A Bruin; Masja de Haas
Journal:  J Thromb Haemost       Date:  2020-04-12       Impact factor: 5.824

7.  Anti-platelet antibody immunoassays in childhood immune thrombocytopenia: a systematic review.

Authors:  David E Schmidt; Anke J Lakerveld; Katja M J Heitink-Pollé; Marrie C A Bruin; Gestur Vidarsson; Leendert Porcelijn; Masja de Haas
Journal:  Vox Sang       Date:  2020-02-20       Impact factor: 2.144

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.